

**DATE** APRIL 2015  
**ISSUE** 1

## HELPFUL NUMBERS FOR PROVIDERS

Passport Health Plan  
Magellan: 1-800-846-7971  
Bin: 016523  
Processor control: 747

## HELPFUL NUMBERS FOR MEMBERS

Passport Health Plan  
800-578-0603

## WEBSITE

[www.passporthealthplan.com](http://www.passporthealthplan.com)

## NEW IN THIS ISSUE

- Pharmacy Tips & Reminders
  - Long-Acting Narcotic Overrides
  - Opioid Quantity Limits
  - 90 Day Fill Reminder
  - Specialty Pharmacy Network
- Recent FDA Advisories

## Pharmacy Tips and Reminders

### Long-Acting Narcotic Overrides:

Passport has revised its criteria so that all long-acting narcotic products will require a prior authorization (PA). (Exceptions exist for Hospice, Long Term Care, and Oncology patients.) The messaging that will appear on rejection is as follows: **O/R allowed for oncologists, hospice, and transition LTC pts, NCPDP 75-Prior authorization required.** The PA criteria for these products have also been updated to include more clinical measures to ensure their safe and effective usage. For more information on the criteria or to receive a copy of the criteria, please contact Magellan Pharmacy Help Desk at 1-800-846-7971.

### Pharmacist Action Required:

- If the **prescription was issued by an Oncologist**, please enter **Submission Clarification Code 99** for oncologists to bypass the Prior Authorization requirement.
- **If the prescription is NOT issued by an Oncologist**, but the member is an oncology patient, the pharmacist may contact Magellan Pharmacy Help Desk at 1-800-846-7971 for a manual override.
- If the member is in Hospice care, please enter **Patient Resident Code 11** for Hospice.
- If the member is in Long Term Care, please enter **Patient Resident Code 4** for LTC.

### Opioid Quantity Limits:

Passport has updated and applied quantity limits for all opioids (short-acting and long-acting). Point-of-sale overrides are available for members with pain due to cancer (**Submission Clarification Code 99**), those in Hospice (**Patient Resident Code 11**), and those transitioning out of long-term care (**Patient Resident Code 4**).

### 90-Day Fill Reminder:

A member must qualify for a 90-day supply of an approved medication. If the member has **had at least 90 days** of therapy in the last 180 days, the claim will **DENY** and the following messaging will be displayed - **“Disp 90d Rx or use ovr code.”** Members are not eligible for a 90-day fill of an approved medication on the first prescription fill. Please enter override code 909090 for a one-time 30-day supply if the prescriber cannot be reached

*All medications may be subject to edits to limit quantities dispensed, day's supply, and drug-drug interactions at the point of service. Pharmacy and Therapeutic Committee decisions are based upon relevant medical literature that is evidence based and peer reviewed. Price(s) listed are calculated based on Wholesale Acquisition Cost (WAC) published by First Data Bank. The cost of therapy is calculated based on a 30 days' supply unless otherwise indicated. This information is to be used as a reference and/or a learning tool for providers.*

in a reasonable amount of time. If the prescriber does not feel it is appropriate to give the member a 90-day supply, or if the member currently resides in a long-term care facility, please use override code 303030 and document on the prescription.

### Specialty Pharmacy Network:

On behalf of Passport Health Plan, MagellanRx is establishing a new network to better manage specialty products. **If you currently dispense specialty products for Passport members and wish to continue filling these products, your pharmacy will need to apply and contract to be a participating provider in this network.** Please contact Magellan Provider Operations at 1-800-441-6001. Once this network is implemented, your pharmacy will NOT be able to fill for specialty products until you have completed the credentialing process.

## Recent Federal Drug Administration (FDA) Advisories Affecting Network Pharmacies and Providers

The FDA recently issued the following advisories:

- 11/25/14      Tecfidera (dimethyl fumarate) by Biogen Idec: Drug Safety Communication - Case of Rare Brain Infection PML Reported.** The FDA is warning that a patient with multiple sclerosis (MS) who was being treated with Tecfidera (dimethyl fumarate) developed a rare and serious brain infection called progressive multifocal leukoencephalopathy (PML), and later died. The patient who died was not taking any other drugs that affect the immune system or drugs that are thought to be associated with PML. As a result, information describing this case of PML is being added to the Tecfidera drug label. Tell patients taking Tecfidera to contact you if they develop any symptoms that may be suggestive of PML (progressive weakness on one side of the body or clumsiness of limbs; disturbance of vision; and changes in thinking, memory and orientation, leading to confusion and personality changes). Monitor lymphocyte counts in Tecfidera-treated patients according to approved labeling.
- 12/09/14      Dietary Supplements Containing Live Bacteria or Yeast in Immunocompromised Persons: Warning - Risk of Invasive Fungal Disease.** The FDA is warning health professionals of the risks associated with the use of dietary supplements containing live bacteria or yeast in immunocompromised persons. A premature infant administered a dietary supplement, ABC Dophilus Powder (Solgar), as part of in-hospital course of treatment, developed gastrointestinal mucormycosis caused by the mold *Rhizopus oryzae* and died. *Rhizopus oryzae* mold was found to be present as a contaminant in an unopened container of the ABC Dophilus Powder, which is formulated to contain three species of live bacteria. Dietary supplements are generally not regulated as drugs by the FDA. These products are not subject to FDA's premarket review or approval requirements for safety and effectiveness, nor to the agency's rigorous manufacturing and testing standards for drugs, including testing for extraneous organisms. The FDA encourages health care providers who use dietary supplements containing live bacteria or yeast as drugs (e.g., to treat, mitigate, cure, or prevent a disease or condition) to submit an Investigational New Drug Application (IND) for FDA review.
- 12/11/14      Ziprasidone (Marketed as Geodon and Generics): Drug Safety Communication - Rare But Potentially Fatal Skin Reactions.** The FDA is warning that the antipsychotic drug ziprasidone is associated with a rare but serious skin reaction that can progress to affect other parts of the body. A new warning has been added to the Geodon drug label to describe the serious condition known as Drug Reaction with Eosinophilia and Systemic Symptoms

(DRESS). DRESS may start as a rash that can spread to all parts of the body. It can include fever, swollen lymph nodes, and inflammation of organs such as the liver, kidney, lungs, heart, or pancreas. DRESS also causes a higher-than-normal number of eosinophils in the blood. DRESS can lead to death. Health care professionals should immediately stop treatment with ziprasidone if DRESS is suspected.

- 12/23/14** **Mitoxantrone by Hospira: Recall - Confirmed Subpotency and Out-Of-Specification.** Hospira, Inc. announced it has initiated a worldwide voluntary recall to the user level of 10 lots of Mitoxantrone (both human and veterinary), due to confirmed subpotency and elevated impurity levels. Risk factors associated with these types of out of specifications may include the potential for decreased potency which can lead to decreased effectiveness, additional dosing and the potential for cumulative impurity toxicity requiring medical intervention. Affected lots were distributed to hospitals and veterinary clinics worldwide from February 2013 through November 2014.
- 3/3/15** **FDA to Require Warning on Labels of Testosterone Products.** An FDA review of safety studies suggests there is possibly an increased risk of cardiovascular events such as heart attack and stroke linked to testosterone use. Manufacturers of all FDA-approved testosterone products must change labeling to clarify approved uses of these medications and include information about the possibility of increased risk of cardiovascular events. Testosterone is only approved for treatment of low testosterone in men due to certain medical conditions confirmed by laboratory testing. Safety and benefits from testosterone treatment for low testosterone due to aging has not been established and is not an FDA-approved treatment option. Any patient experiencing symptoms such as chest pain, shortness of breath, slurred speech, or weakness on one part/side of the body should seek medical attention immediately.

Please visit [www.fda.gov/opacom/7alerts.html](http://www.fda.gov/opacom/7alerts.html) for more information.